Vaccine Vision

Vaccines, with few exceptions, are known somewhat pejoratively as jabs (Fierce Vaccines Weekly Newsletter) and require refrigeration. Vaccines, in the main, are administered by intramuscular injection by trained health care professionals. The major cost of most vaccines is not the vaccine sales price from the Pharmaceutical Industry. Rather, the major cost is the distribution of the vaccines and their administration. Distribution requires a cold chain which means refrigeration which in turn means reliable electricity. Administration requires a health care professional who can maintain sterility of the vaccine from the vial, to a hypodermic syringe and needle, to intramuscular injection. For example, the breakdown of the reimbursements in October 2015 for a flu shot was $12 for the vaccine, and $33 for the administration of the vaccine.

Verndari intends to reduce the dependence on the cold chain and the health care professional. Verndari has developed and applied for patents for our MicroArray Patch (MAP) design and an automated MicroArray Manufacturing System (MAP MS).  Our vaccines will be stable at room temperature and are administered with a painless skin patch. The manufacturing process is robust, inexpensive and can be manufactured on a large scale.   Our MicroArray Patch is a platform for delivering existent and new vaccines.  This design will substantially lower the cost of vaccines by eliminating the need for a hypodermic needle, eliminating the need for highly paid medical professionals to administer a vaccine and by eliminating dependence on the cold chain.

Verndari is also developing a rapid response vaccine platform technology capable of responding to changes in influenza within weeks. This rapid response platform technology could also address other epidemic and biological threats.

The worldwide market for vaccines today is approximately $15 billion and growing at over 12% per year. In developed countries, vaccines have had a profound effect by preventing at least twelve infectious diseases in children. Much work remains to be done, especially globally.

Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
Featured Team Member

Dr. D. R. Henderson
Chief Executive Officer

Dan has experience and success in founding and building biopharmaceutical companies. He holds a Ph.D. in Medical Sciences from the University of New Mexico School of Medicine and was a postdoctoral scholar at Duke University Medical Center. He founded Microgenics Corporation. At Microgenics, Dan invented the CEDIA™ immunoassay system used in clinical laboratories throughout the world. CEDIA™ immunoassays now sell over $1B annually: please see www.usdiagnostics.roche.com and then search for CEDIA™ on their website; repeat at www.thermofisher.com. For this work, the American Association for Clinical Chemistry (AACC) awarded the 2015 biennial Ullman Prize for Technology Innovation to Dr. Henderson.

Dan also founded Calydon where he genetically engineered adenovirus targeting prostate cancer. For this work he was recognized as one of the two pioneers in the field of oncolytic virotherapy (Scientific American, “Tumor Busting Viruses”, October 2003). Calydon was sold to Cell Genesys. 2015 saw the first FDA approved oncolytic virus, a herpesvirus for melanoma.

Dr. Henderson also co-founded PaxVax, a manufacturer and developer of vaccines for travelers to countries without adequate water sanitation (Typhoid, Cholera and Hepatitis A) and the U.S. Military (Anthrax) (see www.paxvax.com). PaxVax was named Best Early-Stage Vaccine Biotech company at the 16th annual World Vaccine Congress in Washington, D.C., March, 2016 and received FDA approval for a Single Dose Oral Cholera vaccine in June. Dan holds 34 issued US Patents.

read more